Ascend Advanced Therapies at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Ascend Advanced Therapies brings 5 presentations to ESGCT 2026 in Hamburg. Its contributions centre on recombinant AAV process development, from suspension production and HEK293 platform choice to purification by ultracentrifugation and chromatography. A further strand compares approved AAV formulations for composition, stability and route of administration.
| Organization | ESGCT 2026 Attendance |
|---|---|
Ascend Advanced Therapies Rockville, Maryland | |
Contract development and manufacturing for gene and cell therapies, from early research to commercial supply; combined with ABL since 2024. | Poster Thu Oct 29 2:00pm–4:00pm A cross-sectional analysis of approved AAV gene therapy formulations linking composition, stability, and clinical administration Poster Thu Oct 29 2:00pm–4:00pm A surrogate assay to monitor replication-competent AAV formation using nanopore long-read sequencing Poster Thu Oct 29 2:00pm–4:00pm Enhancing recombinant AAV production in suspension cell culture through targeted cell cycle modulation Poster Thu Oct 29 2:00pm–4:00pm Navigating AAV Manufacturing Complexity: A Comprehensive Comparison of Commercial and Proprietary HEK293 Platforms for Optimized Vector Quality Poster Thu Oct 29 2:00pm–4:00pm Orthogonal purification strategies for AAV: bridging rapid feasibility via ultracentrifugation with scalable chromatography-based manufacturing to support diverse therapeutic timelines. |
Instantly find 20 buyers from Ascend Advanced Therapies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction